Raltegravir

Drug Profile

Raltegravir

Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 30 May 2017 Adverse events and efficacy data from a phase III trial in HIV-1 infections released by Merck
  • 26 May 2017 Registered for HIV-1 infections (Combination therapy, Treatment-naive, Treatment-experienced) in USA (PO, 1200mg once daily)
  • 19 May 2017 Committee for Medicinal Products for Human Use recommends approval of raltegravir for HIV-1 infections (Combination therapy, Treatment-naive, Treatment-experienced) in European Union (PO, 1200mg once daily)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top